20th June 2022 | Pharma Updates
Analysts from Jefferies India give Sun Pharma double thumbs up
Sun Pharma’s growth, according to the firm, will be driven by its specialty portfolio and the India market from now on. Jefferies believes it can meet this goal since it is no longer reliant on its generic portfolio, which is more susceptible to price erosion.
This large-cap pharmaceutical company set a record date for Rs 150 dividend
GlaxoSmithKline Pharmaceuticals Ltd is a large cap pharmaceutical company that makes a wide range of pharmaceutical medications, vaccines, and some of the greatest pharma goods on the market. The record date for a total dividend purpose of Rs 150 has been set for July 8, 2022.
Tamil Nadu: Health-care technology on the rise
Tamil Nadu ranks poorly in terms of healthcare innovation and R&D for a state that is a medical tourism hotspot. However, industry observers claim that there are signs of life. The majority of specialists who spoke with the TOI placed their faith in the IIT-Madras ecosystem.
Market for anti-obesity prescriptions will be enormous by 2030
Market Strides, a leading global industry research agency, is happy to announce the release of its new report on the Anti-Obesity Prescription Market, which covers all areas of the market and provides up-to-date data on current trends, with a projection for 2022-2030.
Dupixent approved by FDA as a first-line treatment for eosinophilic esophagitis
USFDA has approved Dupixent 300 mg weekly to treat patients with eosinophilic esophagitis (EoE) aged 12 years and older who weigh at least 40 kg. With this clearance, Dupixent becomes the first and only drug in the United States that is expressly authorised to treat EoE.
Sanofi signed clinical research and AI screening partnership with Abu Dhabi's health authority
“The relationship reinforces Abu Dhabi’s continuous efforts to promote itself as a top life science destination and an innovation hub, ” according to the department’s announcement.
Imcivree, a hereditary obesity medication, receives second approval
Rhythm Pharmaceuticals has won FDA approval for its obesity management medicine for people with ultra-rare genetic diseases for the second time, this time for Bardet-Biedl syndrome, a disease that affects a variety of organs but has early-onset obesity as a key symptom.
